Dual inhibition of HERs and PD-1 counteract resistance in KRASG12C-mutant head and neck cancer
Abstract Background Basket clinical trials targeting the KRASG12C-mutation in solid tumors have shown initial promise, including in orphan KRASG12C head and neck cancer (HNC). However, development of resistance to KRASG12C-mutant-specific inhibitors (KRASG12Ci) remains a major obstacle. Here, we inv...
Saved in:
| Main Authors: | Ofra Novoplansky, Sankar Jagadeeshan, Manu Prasad, Ksenia M. Yegodayev, Divyasree Marripati, Raghda Abu Shareb, Yariv Greenshpan, Sooraj Mathukkada, Talal Ben-Lulu, Baisali Bhattacharya, Angel Porgador, Dexin Kong, Johannes Brägelmann, J. Silvio Gutkind, Moshe Elkabets |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-11-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13046-024-03227-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
by: Constanza Tapia Contreras, et al.
Published: (2025-02-01) -
Reactivation of MAPK-SOX2 pathway confers ferroptosis sensitivity in KRASG12C inhibitor resistant tumors
by: Kai Wang, et al.
Published: (2024-12-01) -
Sotorasib resistance triggers epithelial-mesenchymal transition and activates AKT and P38-mediated signaling
by: Raquel Arantes Megid, et al.
Published: (2025-01-01) -
Selective epithelial expression of KRASG12D in the Oncopig pancreas drives ductal proliferation and desmoplasia that is accompanied by an immune response
by: Carlos P. Jara, et al.
Published: (2025-02-01) -
MRTX1133 attenuates KRASG12D mutated-colorectal cancer progression through activating ferroptosis activity via METTL14/LINC02159/FOXC2 axis
by: Junwei Zou, et al.
Published: (2025-02-01)